New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and Rwanda could be among the first to deploy it, government and World Health ...

Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S. rapidly scaling back foreign aid contributions, the UN has released a new ...

And another study says people with HIV are too often excluded from cancer trials.  And another study says people with HIV are ...

M orris Singletary’s experience of living with HIV is typical of many gay men. It includes denial, anger, fear and acceptance. Where he perhaps differs from many is that he’s used his experience to ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial progress. Many effective treatments are available for HIV, but these ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.

A new UVA study finds that HIV drugs like NRTIs may reduce Alzheimer's risk by 10% annually, suggesting potential for repurposing in dementia prevention.

A class of HIV drugs known as nucleotide reverse transcriptase inhibitors (NRTIs) may help prevent Alzheimer’s disease, reducing risk by up to 13%, a new study suggests.